Skip to content
The Policy VaultThe Policy Vault

Ofev (nintedanib) — United Healthcare

Chronic fibrosing interstitial lung disease with a progressive phenotype

Initial criteria

  • Diagnosis of chronic fibrosing interstitial lung disease (ILD) with a progressive phenotype

Reauthorization criteria

  • Documentation of positive clinical response to Ofev therapy

Approval duration

12 months